Platelets in tumor metastasis: generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential.
Human 253J urinary carcinoma cells and the F1 (low-metastatic) and F10 (high-metastatic) variants of the B16 murine melanoma cell line have been shown to activate heparinized human platelets by an adenosine diphosphate (ADP)-dependent mechanism based on inhibition by creatine phosphate/creatine phosphokinase and the identification of aggregating concentrations (1 to 2 mumol/L) of ADP in cell-free culture supernatants by high-performance liquid chromatography. Aggregation did not occur in citrated samples, and hirudin was without effect. Studies were carried out to determine whether extracellular ADP arose from nonspecific cell damage during cell isolation and manipulation or was a specific process under control of the tumor cells themselves. Tumor cell damage during harvesting was shown not to be a factor because the amounts of ADP produced by the three cell lines (a) were inversely related to the appearance of lactic dehydrogenase in the culture supernatants and (b) were similar when measured in confluent monolayers, either in tumor cells after detachment and resuspension or after crossover studies involving culture in, alternatively, Hanks' balanced salt solution and minimal essential medium. Metabolic control of ADP production was indicated by the fact that (a) it was not dependent on cell number, which suggests feedback inhibition; (b) it was reduced 60% when tumor cells were treated with p-chloromercuribenzene sulfonate; and (c) it was completely abolished in those treated with iodoacetic acid, which might be expected to increase nonspecific leakage. These studies indicate that ADP production by these three lines does not arise due to leakage induced by nonspecific membrane damage during cell harvesting and manipulation but is a discrete process under metabolic control of the tumor cells. Moreover, in B16 murine melanoma cells the ability to produce ADP and to support platelet aggregation appears to be unrelated to metastatic potential insofar as identical results were obtained with the F1 and F10 variants.
Grignani
G
G
American Red Cross Laboratories, Rockville, MD.
Jamieson
G A
GA
D002731:4-Chloromercuribenzenesulfonate / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000502:physiology; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D002277:Carcinoma / Q000097:blood; D002460:Cell Line; D006801:Humans; D007461:Iodoacetates / Q000494:pharmacology; D007700:Kinetics; D008546:Melanoma, Experimental / Q000097:blood; D051379:Mice; D009362:Neoplasm Metastasis; D010974:Platelet Aggregation / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000378:metabolism*; D014571:Urologic Neoplasms / Q000097:blood
D007461:Iodoacetates; D002731:4-Chloromercuribenzenesulfonate; D000244:Adenosine Diphosphate